Skip to content

Mitoxantrone Classification Essay

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.[PubMed]

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.[PubMed]

3. Drabu S, Khatri S, Babu S, Verma D. Nanotechnology: An introduction to future drug delivery system. J Chem Pharm Res. 2010;2(1):171–179.

4. Chakraborty C, Sarkar B, Hsu CH, Wen ZH, Lin CS, Shieh PC. Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol. 2009;93(2):285–286.[PubMed]

5. Ulbrich W, Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J R Soc Interface. 2010;7(Suppl 1):S55–S66.[PMC free article][PubMed]

6. Wikberg M, Ulmius J, Ragnarsson G. Review article: Targeted drug delivery in treatment of intestinal diseases. Aliment Pharmacol Ther. 1997;11(Suppl 3):109–115.[PubMed]

7. Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11(10):751–761.[PubMed]

8. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135–146.[PubMed]

9. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005;2(4):369–381.[PubMed]

10. Wang X, Yang L, Chen Z, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58(2):97–110.[PubMed]

11. D’Souza G, Weissig V. Weissig W, D’Souza GGM. Organelle-Specific Pharmaceutical Nanotechnology. Hoboken, NJ: John Wiley & Sons, Inc; 2010. An introduction to subcellular nanomedicine: current trends and future developments; pp. 1–13.

12. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J Am Chem Soc. 2010;132(5):1517–1519.[PubMed]

13. de la Fuente JM, Berry CC. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem. 2005;16(5):1176–1180.[PubMed]

14. Flierl A, Jackson C, Cottrell B, Murdock D, Seibel P, Wallace DC. Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol Ther. 2003;7(4):550–557.[PubMed]

15. Lai S, Hida K, Man ST, et al. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials. 2007;28(18):2876–2884.[PubMed]

16. Rajendran L, Knölker HJ, Simons K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov. 2010;9(1):29–42.[PubMed]

17. Cheng SM, Boddapati SV, D’Souza G, Weissig V. Nanotechnology for Cancer Therapy. Boca Raton, FL: CRC/Taylor and Francis; 2006. DQAsomes as mitochondria-targeted nanocarriers for anti-cancer drugs; pp. 787–802.

18. Bareford L, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59(8):748–758.[PMC free article][PubMed]

19. Neekhra N, Padh H. An insight into molecular mechanism of endocytosis. Indian J Biochem Biophys. 2004;41(2–3):69–80.[PubMed]

20. García-García E, Rosales C. Signal transduction during Fc receptor-mediated phagocytosis. J Leukoc Biol. 2002;72(6):1092–1108.[PubMed]

21. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593–623.[PubMed]

22. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8):1183–1189.[PubMed]

23. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.

Dear Colleagues,

Worldwide, human cancer occurs with increasingly higher incidences and mortalities. The traditional diagnostic practice for this disease is mainly based on histological patterns. Recent research supports the notion that cancer is not a single malignant disorder, but rather, a group of distinct molecular diseases. In the era of precision medicine with targeted therapies, there is an imperative need to overcome the limitations of the conventional classification system, so as to accurately stratify patients to achieve maximum therapeutic efficacy. As such, many molecular diagnostic tests have been developed to identify the underlying genetic signatures and incorporate them into the conventional histopathological classifications of cancers.

The profiling of cancer has yielded a number of genetic, microRNA, proteomic, metabolic, and imaging markers for molecular classification. Newer approaches include, but are not limited to, cancer stem cell analysis and next-generation sequencing. Indeed, molecular classification has already been extensively applied to some types of cancer, such as the subtypes of luminal A and lumina B estrogen receptor-positive breast cancer, the subtypes of ALK- and EGFR-positive non-small cell lung cancer, the subtypes of WNT pathway and Sonic Hedgehog pathway medulloblastoma, etc. This Special Issue discusses the significance of molecular classification and its impact on the diagnosis of, and rational therapy for cancer.

Dr. William Chi-shing Cho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer biomarker
  • cancer stem cells
  • clinical trial
  • copy number variation
  • cytogenetics
  • diagnostic imaging
  • digital PCR
  • epigenomics
  • fluorescence in situ hybridization
  • genome-wide association studies
  • genomic database
  • genomics
  • immunohistochemistry
  • metabolomics
  • methylation
  • microarray
  • microfluidics, nanofluidics
  • microRNA
  • molecular classification
  • molecular diagnostics
  • molecular tumor pathology
  • next-generation sequencing
  • non-coding RNAs
  • omics
  • PCR array
  • personalized medicine
  • post-translational modifications
  • precision medicine
  • proteomics
  • single nucleotide polymorphism
  • targeted therapy
  • theranostics
  • translational cancer research

Related Special Issue